ライフサイエンスコーパス: donor lymphocyte infusion

1 ans for augmenting the GVL effect of delayed donor lymphocyte infusion.

2 the graft-versus-leukemia effects of delayed donor lymphocyte infusion.

3 by day 200 after cyclosporine withdrawal and donor lymphocyte infusion.

4 rdizing the graft-versus-leukaemia effect of donor lymphocyte infusion.

5 sease occurred in 5 of 14 RIC patients after donor lymphocyte infusion.

6 5 days post-transplantation and responded to donor lymphocyte infusion.

7 resolved after treatment with rituximab and donor lymphocyte infusion.

8 nd one was reinduced into continuous CR with donor lymphocyte infusion.

9 omplete donor chimerism without the need for donor lymphocyte infusion.

10 of the anti-leukemia response in vivo after donor lymphocyte infusion.

11 a complete cytogenetic remission after CD4+ donor lymphocyte infusion.

12 se (GVHD), and the toxic effects of adjuvant donor-lymphocyte infusion.

13 GVHD and seven (14%) had chronic GVHD before donor-lymphocyte infusion.

14 unotherapy of hematologic malignancies using donor lymphocyte infusions.

15 found to inhibit the GVL response of delayed donor lymphocyte infusions.

16 l transplantation (alloTCD-HSCT) followed by donor lymphocyte infusions.

17 e response with reduced immunosuppression or donor lymphocyte infusions.

18 pse either prior to or during treatment with donor lymphocyte infusions.

19 ent was accomplished only following multiple donor lymphocyte infusions.

20 s a platform for adoptive immunotherapy with donor lymphocyte infusions.

21 The sensitivity of CML to donor lymphocyte infusion after allogeneic stem cell tra

22 The majority of patients treated with donor lymphocyte infusions after relapse responded, demo

23 xperienced a complete remission after CD4(+) donor lymphocyte infusions also developed high-titer ant

24 e use of immune modulating therapies such as donor lymphocyte infusion and azacitidine.

25 ere isolated from peripheral blood after CD4 donor lymphocyte infusion and recognition of donor-deriv

26 Such treatment, as an adjunct to donor lymphocyte infusions and pharmacologic therapy, ma

27 Donor lymphocyte infusions are associated with a signifi

28 Donor lymphocyte infusions are extremely effective for c

29 phenotype, were administered as a preemptive donor lymphocyte infusion at day 14 post-HCT.

30 Ten patients received low-dose donor lymphocyte infusions beginning 5 months after tran

31 Twelve patients received donor lymphocyte infusions +/- chemoimmunotherapy for re

32 Thirteen patients had undergone salvage donor lymphocyte infusion (DLI) (median time from DLI to

33 c cells, we assessed whether GVHD induced by donor lymphocyte infusion (DLI) affects the persistence,

34 CD8+ T cell-depleted (TCD) donor lymphocyte infusion (DLI) after TCD allogeneic hem

35 Ten dogs also received escalating doses of donor lymphocyte infusion (DLI) alone or with pentostati

36 LVL (mean, 11 L) to collect lymphocytes for donor lymphocyte infusion (DLI) and other therapies was

37 In addition, 17 patients received donor lymphocyte infusion (DLI) as interventional therap

38 geneic stem cell graft followed by postponed donor lymphocyte infusion (DLI) can experience graft-ver

39 Donor lymphocyte infusion (DLI) can restore complete rem

40 Donor lymphocyte infusion (DLI) can restore durable mole

41 In the current study, we examined whether donor lymphocyte infusion (DLI) could be used as adoptiv

42 raft-versus-leukemia-based therapies such as donor lymphocyte infusion (DLI) for chronic myelogenous

43 te for patients who achieved remission after donor lymphocyte infusion (DLI) for progression, was 65%

44 Donor lymphocyte infusion (DLI) has been used in postnat

45 Donor lymphocyte infusion (DLI) has been used to enhance

46 atched, nonmyeloablative allogeneic SCT with donor lymphocyte infusion (DLI) in patients with lymphoi

47 (MMB3.19) were administered 7 days following donor lymphocyte infusion (DLI) or RLI on day 35.

48 geneic bone marrow transplantation (BMT) and donor lymphocyte infusion (DLI) provide valuable treatme

49 Donor lymphocyte infusion (DLI) re-establishes failing g

50 Donor lymphocyte infusion (DLI) reliably induces durable

51 Prophylactic donor lymphocyte infusion (DLI) strategies are recommend

52 Delayed administration of donor lymphocyte infusion (DLI) to established mixed chi

53 Donor lymphocyte infusion (DLI) was administered in 26 e

54 Fifty-three of 446 patients received donor lymphocyte infusion (DLI) with a median CD3 dose o

55 Donor lymphocyte infusion (DLI), a standard relapse trea

56 ulations play a critical role in response to donor lymphocyte infusion (DLI), an established and pote

57 lant may achieve durable remission following donor lymphocyte infusion (DLI), showing the potency of

58 Donor lymphocyte infusion (DLI), whereby donor mononucle

59 their phenotype, and their role in governing donor lymphocyte infusion (DLI)-mediated alloresponses.

60 ion; 2 of these patients received concurrent donor lymphocyte infusion (DLI).

61 ute hepatitislike presentation of GVHD after donor lymphocyte infusion (DLI).

62 ow grafts, exceeding the survival benefit of donor lymphocyte infusion (DLI).

63 verted to full donor chimerism by the use of donor lymphocyte infusion (DLI; P = .03).

64 performed of the response to treatment with donor lymphocyte infusions (DLI) and the survival in 66

65 Donor lymphocyte infusions (DLI) can induce remissions i

66 The clinical efficacy of donor lymphocyte infusions (DLI) in patients with relaps

67 Donor lymphocyte infusions (DLI) provide effective thera

68 disease (GVHD) by delayed administration of donor lymphocyte infusions (DLI) to established mixed ch

69 We evaluated the ability of donor lymphocyte infusions (DLI) to mediate GVL effects

70 cal immunosuppression on the in vivo fate of donor lymphocyte infusions (DLI)-derived T cells, their

71 The use of donor lymphocytes infusion (DLI) continues to treat rela

72 The effectiveness of donor-lymphocyte infusion (DLI) for treatment of relapse

73 lymphocytes from the original marrow donor (donor lymphocyte infusions [DLI]) is remarkably effectiv

74 Donor lymphocyte infusions (DLIs) 35 days after bone mar

75 tem cell transplantation (HSCT) and received donor lymphocyte infusions (DLIs) after transplantation.

76 after reduced-intensity allografts and while donor lymphocyte infusions (DLIs) can be effective salva

77 of this strategy remains of interest because donor lymphocyte infusions (DLIs) can induce a potent gr

78 Donor lymphocyte infusions (DLIs) can produce lasting re

79 nancies often are treated with unmanipulated donor lymphocyte infusions (DLIs) from the transplant do

80 We describe the toxicity and efficacy of donor lymphocyte infusions (DLIs) given to 81 patients (

81 Donor lymphocyte infusions (DLIs) induce effective graft

82 Donor lymphocyte infusions (DLIs) induce potent graft ve

83 y the mechanisms governing the activation of donor lymphocyte infusions (DLIs) manifesting as lymphoh

84 We aimed to assess the impact of donor lymphocyte infusions (DLIs) on relapse incidence w

85 The ability of donor lymphocyte infusions (DLIs) to induce complete res

86 Donor lymphocyte infusions (DLIs) were given to 14 patie

87 Dendritic cell vaccines and donor lymphocyte infusions (DLIs) were incorporated into

88 ent of animals with NST, posttransplantation donor lymphocyte infusions (DLIs), and a vaccine, compri

89 y that persisted after alloHSCT and standard donor lymphocyte infusions (DLIs).

90 ronic myeloid leukemia patients who received donor lymphocyte infusions following transplant relapse.

91 ntation is being explored through the use of donor lymphocyte infusions for patients who have relapse

92 Donor lymphocyte infusions for treatment of relapse afte

93 16 (33%) patients received donor-lymphocyte infusion from 3 months after transplant

94 Since donor lymphocyte infusions have clinical activity in JMM

95 n proven by the demonstration of response to donor lymphocyte infusion in patients relapsing after al

96 The ability to induce remissions with donor lymphocyte infusion in patients with CLL, Richter'

97 evidence for its presence is the efficacy of donor lymphocyte infusions in generating anti-tumor resp

98 Donor lymphocyte infusion induced GVHD in nine of 23 pat

99 Unfortunately, donor lymphocyte infusion induced severe cortisone-resis

100 hematopoietic stem cell transplantation and donor lymphocyte infusion is essential for acute graft v

101 Prophylactic or preemptive donor lymphocyte infusion may be useful, but requires co

102 Donor lymphocyte infusions may also be used both prophyl

103 osuppression, antiviral therapy, unprocessed donor lymphocyte infusion, mobilized peripheral blood pr

104 meliorated the severity of GVHD in a delayed donor lymphocyte infusion model.

105 nt research is focusing on methods of making donor lymphocyte infusions more effective in the nonchro

106 ant cells or mixed chimerism could receive a donor lymphocyte infusion of 0.5 to 2 x 10(8) mononuclea

107 by cytoreductive therapy, followed either by donor lymphocyte infusion or second HSCT for consolidati

108 eduction of immune suppression plus or minus donor lymphocyte infusion or stem cell boost, which stab

109 Adjusting the timing and dose of donor lymphocyte infusion reduces the risk of graft-vers

110 patient peripheral blood at the time of the donor lymphocyte infusion response.

111 Subsequent donor lymphocyte infusion resulted in a significant chan

112 eated for relapsed MM after alloTCD-HSCT and donor lymphocyte infusions, supporting the development o

113 All types of cell-based therapies, from donor lymphocyte infusion to dendritic cell vaccines, an

114 chimerism in the presence of GVHD after CD4 donor lymphocyte infusion was observed in a patient, HLA

115 Donor lymphocyte infusions were given as part of the RIS

116 Escalating doses of donor lymphocyte infusions were given from 6 months afte

117 Donor lymphocyte infusions were given to 18 patients eit

118 nd can preclude the administration of graded donor lymphocyte infusions, which may optimize the thera